 |
|
New study shows potential to treat or prevent viral cancers
June 17, 2008New therapies may offer 'exquisite specificity,' according to researchers
NEW ORLEANS, La.-A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.
"There is an urgent need to find new approaches to treating and preventing viral cancers," said Ekaterina (Kate) Dadachova, associate professor of nuclear medicine and microbiology and immunology at Albert Einstein College of Medicine, Bronx, N.Y. and lead researcher of the study, Viral Antigens as Novel Targets for Radioimmunotherapy of Viral Cancers. "The magnitude and global health-burden associated with viral cancers is only now being realized."
It is estimated that up to 25 percent of all cancers are currently linked to existing viral infections. Most of these cancers are extremely difficult to treat and cannot successfully be reduced or removed using conventional therapies or treatments. Viral cancers include cervical cancers caused by infection with a human papillomavirus (HPV), a sexually transmitted disease; hepatocellular carcinoma (HCC), a cancer of the liver; various lymphomas and carcomas in patients with AIDS/HIV; and other cancers.
According to Dadachova, this is the first time that researchers have attempted to target viral antigens on cancers, although the use of RIT for the treatment of cancer has been under development for thirty years. However, the targets of RIT therapy to date have included only "self" human antigens, which are overexpressed on the tumors but also expressed on normal tissues. Viral antigens, on the contrary, are expressed only on the tumors and nowhere else in the body.
The idea to perform the study was suggested by Dr. Arturo Casadevall, chair of the department of microbiology and immunology at Albert Einstein College of Medicine, who collaborates with Dadachova on developing radioimmunotherapy of infectious diseases and cancers. The study involved treating experimental cervical cancer and hepatocellular carcinoma in nude mice with antibodies to respective viral antigens expressed on these tumors. The antibodies were radiolabeled with 188-Rhenium-a powerful beta-emitting radionuclide. "This study demonstrates a real possibility for more specifically targeted cancer treatments," said Dadachova. "Targeting those antigens with radiolabeled molecules offers exquisite specificity-and will hopefully allow us to significantly increase the efficacy of treatment by administering more individualized doses while avoiding toxicity."
"Nuclear medicine and molecular imaging offer the ability to target disease on a truly molecular level that is unmatched by any other imaging or therapeutic modality," said Dadachova. "Targeting viral antigens with radiolabeled antibodies (or also with specific peptides or aptamers) will allow the extremely precise diagnosis of such cancers and their effective therapy. Furthermore, this approach will make possible 'molecular prevention' of viral cancers, when infected cells will be targeted before they become cancerous."
Society of Nuclear Medicine
It is estimated that up to 25 percent of all cancers are currently linked to existing viral infections. Most of these cancers are extremely difficult to treat and cannot successfully be reduced or removed using conventional therapies or treatments. Viral cancers include cervical cancers caused by infection with a human papillomavirus (HPV), a sexually transmitted disease; hepatocellular carcinoma (HCC), a cancer of the liver; various lymphomas and carcomas in patients with AIDS/HIV; and other cancers.
According to Dadachova, this is the first time that researchers have attempted to target viral antigens on cancers, although the use of RIT for the treatment of cancer has been under development for thirty years. However, the targets of RIT therapy to date have included only "self" human antigens, which are overexpressed on the tumors but also expressed on normal tissues. Viral antigens, on the contrary, are expressed only on the tumors and nowhere else in the body.
The idea to perform the study was suggested by Dr. Arturo Casadevall, chair of the department of microbiology and immunology at Albert Einstein College of Medicine, who collaborates with Dadachova on developing radioimmunotherapy of infectious diseases and cancers. The study involved treating experimental cervical cancer and hepatocellular carcinoma in nude mice with antibodies to respective viral antigens expressed on these tumors. The antibodies were radiolabeled with 188-Rhenium-a powerful beta-emitting radionuclide. "This study demonstrates a real possibility for more specifically targeted cancer treatments," said Dadachova. "Targeting those antigens with radiolabeled molecules offers exquisite specificity-and will hopefully allow us to significantly increase the efficacy of treatment by administering more individualized doses while avoiding toxicity."
"Nuclear medicine and molecular imaging offer the ability to target disease on a truly molecular level that is unmatched by any other imaging or therapeutic modality," said Dadachova. "Targeting viral antigens with radiolabeled antibodies (or also with specific peptides or aptamers) will allow the extremely precise diagnosis of such cancers and their effective therapy. Furthermore, this approach will make possible 'molecular prevention' of viral cancers, when infected cells will be targeted before they become cancerous."
Society of Nuclear Medicine
Viral Antigens Current Events and Viral Antigens News RSSEinstein scientists treat cancer as an infectious disease -- with promising results
Researchers at the Albert Einstein College of Medicine of Yeshiva University have shown for the first time that cancers can be successfully treated by targeting the viruses that cause them.
Cellular pathway yields potential new weapon in vaccine arsenal
When a cell has to destroy any of its organelles or protein aggregates, it envelopes them in a membrane, forming an autophagosome, and then moves them to another compartment, the lysosome, for digestion. Two years ago, Rockefeller University assistant professor Christian Münz showed that this process, called autophagy, sensitizes cells for recognition by the immune system's helper T cells.
Molecular switch may turn off immune cells that target HIV
One of the primary mysteries of the AIDS epidemic - why the immune system is unable to control HIV infection - may have been solved by an international research collaborative.
T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
Having their immune system cells go through a laboratory version of boot camp may help patients win their battle against HIV.
Boosting newborns' immune responses
Newborn babies have immature immune systems, making them highly vulnerable to severe infections and unable to mount an effective immune response to most vaccines, thereby frustrating efforts to protect them.
New technique points to safer, more efficient vaccination
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Sounding the alarm for infections: EMBL researchers discover rapid-response, interferon-producing cells
Nearly fifty years ago, researchers discovered that when cells in laboratory cultures are infected by a virus, they secrete a substance that protects other cells from infection. In 1957 Alick Issaks and Jean-Jacques Lindenmann traced this effect to a protein called interferon, a molecule now known to play a key role in the immune system. Human and animal cells produce it in a rapid "first wave" response to infections. Since its discovery, scientists have sought to use this natural substance to cure all sorts diseases, and clinical trials have demonstrated interferon's potential to combat diseases as different as hepatitis C, blood cancers, and multiple sclerosis. Yet many aspects of
More Viral Antigens Current Events and Viral Antigens News Articles
| Human viral hepatitis: Hepatitis-associated antigen and viruses by Arie Jeremy Zuckerman | |
| Immunobiology of Proteins and Peptides III: Viral and Bacterial Antigens (Advances in Experimental Medicine and Biology) by M. Zouhair Atassi | |
| Rapid West Nile virus antigen detection.: An article from: Emerging Infectious Diseases by Nicholas A. Panella, Kristen L. Burkhalter, Stanley, A. Langevin, Aaron C. Brault, Lynn M. Schooley, Brad J. Biggerstaff, Roger S. Nasci, Nicholas Komar This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on October 1, 2005. The length of the article is 2558 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Viral Superantigens Viral Superantigens is the first complete review of this new area of study. Edited by a leading researcher and authored by a distinguished team of contributors, this comprehensive analysis covers every aspect of viral superantigens and related subjects, including critical topics such as effects on the T cell repertoire and viral superantigen-mediated diseases. This book brings readers up to date... |
| Advances in Viral Oncology: The Transformation - Associated Cellular P53 Protein (Advances in viral oncology) | |
| Australia Antigen and Viral Hepatitis (Vox Sanguinis) by International Symposium on Basic Progres | |
| Observations on some viral antigens in cells of bone-marrow tissue by M. A Shestechenko | |
| The immunological response of fish to bacterial and viral antigens: A selected bibliography with abstracts by Irvin C Mohler | |
| The immunoperoxidase method for detection of viral and chlamydial antigens: 1. Basic method and detection of herpes virus equi-1-antigen in livers of infected hamsters by P Teufel | |
| Oncogenesis and Herpesviruses III: Part I DNA of herpesviruses, viral antigens, cell-virus interaction (International Agency for Research on Cancer) |
| © 2008 BrightSurf.com |